SCHEMBL19975360

SCHEMBL19975360

CC(C(O)C(=O)NCC1CCCCC1)N(C=O)C1CCN(CC(F)(F)F)CC1

nearest known ligand 0.35

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 1/20 0.35
KMT2A Q03164 1/20 0.35
ALDH1A1 P00352 4/20 0.33
SMN1; SMN2 Q16637 2/20 0.33
ADH1B P00325 1/20 0.33
ADH1C P00326 1/20 0.33
ADH1A P07327 1/20 0.33
GAA P10253 2/20 0.33
SIGMAR1 Q99720 2/20 0.32
HTR4 Q13639 2/20 0.32
L3MBTL1 Q9Y468 1/20 0.32
TSHR P16473 1/20 0.31
MLYCD O95822 1/20 0.31
HDAC6 Q9UBN7 1/20 0.31
TDP1 Q9NUW8 1/20 0.31
HRH3 Q9Y5N1 1/20 0.31
SMYD3 Q9H7B4 1/20 0.31
KCNH2 Q12809 1/20 0.31
CACNA1I Q9P0X4 1/20 0.31
LIPE Q05469 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19974862 0.85 ADH1B (0.46) MEN1KMT2AALDH1A1SMN1; SMN2ADH1B
SCHEMBL21176194 0.83 ADH1B (0.34) MEN1KMT2AALDH1A1SMN1; SMN2ADH1B
SCHEMBL19975527 0.83 ADH1C (0.46) MEN1KMT2AALDH1A1SMN1; SMN2ADH1B
SCHEMBL19975423 0.77 EPHX1 (0.39) MEN1KMT2AALDH1A1SMN1; SMN2ADH1B
SCHEMBL19975424 0.77 EPHX1 (0.39) MEN1KMT2AALDH1A1SMN1; SMN2ADH1B
SCHEMBL19975043 0.76 SMN1; SMN2 (0.38) MEN1KMT2AALDH1A1SMN1; SMN2GAA
SCHEMBL19975361 0.76 EPHX1 (0.40) MEN1KMT2AALDH1A1SMN1; SMN2GAA
SCHEMBL19975162 0.75 KMT2A (0.33) KMT2ASMN1; SMN2ADH1BADH1CADH1A
SCHEMBL21176292 0.74 KMT2A (0.42) KMT2ASMN1; SMN2ADH1BADH1CADH1A
SCHEMBL30063422 0.74 KMT2A (0.42) KMT2ASMN1; SMN2ADH1BADH1CADH1A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20220356148-A1 ANTIVIRAL COMPOUNDS HAPLOGEN GMBH (AT) 2022-11-10 US disclosed
US-11091428-B2 Antiviral compounds HAPLOGEN GMBH (AT) 2021-08-17 US disclosed
US-11091428-B2 Antiviral compounds HAPLOGEN GMBH (AT) 2021-08-17 US disclosed
US-20190225575-A1 ANTIVIRAL COMPOUNDS LUNIS CONSULTING GMBH (AT) 2019-07-25 US disclosed
US-20190225575-A1 ANTIVIRAL COMPOUNDS LUNIS CONSULTING GMBH (AT) 2019-07-25 US disclosed
EP-3512836-A1 ANTIVIRAL COMPOUNDS Haplogen GmbH (AT) 2019-07-24 EP disclosed
WO-2018050631-A1 ANTIVIRAL COMPOUNDS HAPLOGEN GMBH (AT) 2018-03-22 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20190225575-A1 ANTIVIRAL COMPOUNDS PLA2G1B, PLA2G12A, PLA2G4C MEN1 4331/4885KMT2A 4031/4885ALDH1A1 2271/4885
US-20220356148-A1 ANTIVIRAL COMPOUNDS PLA2G12A, PLA2G1B, PLA2G4C MEN1 4361/4885KMT2A 4177/4885ALDH1A1 2673/4885
US-11091428-B2 Antiviral compounds PLA2G1B, PLA2G12A, PLA2G4C MEN1 4331/4885KMT2A 4031/4885ALDH1A1 2271/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.